Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids | Reuters
Moderna to advance two Omicron vaccine candidates against newer variants
Moderna Is Developing Two Different Omicron-Targeting Booster Shots - WSJ
Trial Details
U.S. government places $1.74B order for Moderna's new Covid-19 vaccine boosters - MedCity News
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
FDA Authorizes Moderna Pfizer BioNTech Bivalent COVID 19 Booster Doses
Moderna says updated booster generated 'significantly higher' neutralizing antibodies against BA.4/BA.5 subvariants - 6abc Philadelphia
Moderna Says Omicron Tailored COVID-19 Shots Shows Better Immune Response Than Original Vaccine
Health Canada grants authorisation for Moderna's Omicron-based booster
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
Moderna completes FDA filing for bivalent COVID-19 booster vaccine, MR
/cloudfront-us-east-2.images.arcpublishing.com/reuters/TCSHY2P5Y5IZLADCIBDXST7MFQ.jpg "Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters")
Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters
Moderna: New booster protects better against variants - The Jerusalem Post
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant | bioRxiv
Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of
Moderna is padding the case for its bivalent COVID-19 booster
Covid, Moderna in Usa chiede ok a vaccino Omicron 4-5 per bimbi e teenager - Enti Locali Online
Moderna on X: "A Phase 2/3 trial for mRNA-1273.222 is currently underway. We have rapidly scaled manufacturing of mRNA-1273.222 to be ready, if authorized, to deliver doses in September. https://t.co/AQG4hfwNe6" / X
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Moderna COVID19 Bivalent vaccine (Original and Omicron BA.4/BA.5)
Moderna on X: "We have submitted a request for emergency use authorization (EUA) for our Omicron-targeting bivalent #COVID19 #vaccine, mRNA-1273.222, in children and adolescents 12 to 17 years of age to the
Moderna to advance two Omicron vaccine candidates against newer variants | Reuters
CDC Recommends Bivalent COVID 19 Boosters
